Obstructive sleep apnea and cardiovascular disease in individuals with metabolic dysfunction-associated fatty liver disease: A prospective cohort study

Abstract

Objective: To assess the association between obstructive sleep apnea (OSA) risk levels and major cardiovascular disease (CVD) subtypes in individuals with metabolic dysfunction-associated fatty liver disease (MAFLD).

Methods: This cohort study included 128,022 MAFLD participants from the UK Biobank without CVD at baseline. OSA risk was assessed using the Berlin Questionnaire. Cardiovascular outcomes, including coronary heart disease (CHD), atrial fibrillation (AF), heart failure (HF), and stroke, were identified via hospital and death records. Cox proportional hazards models estimated the associations between OSA risk levels and CVD events.

Results: Over a median follow-up of 13.6 years, 25,618 CVD events occurred. Compared with participants at low OSA risk, those at high OSA risk were associated with higher CHD (hazard ratios [HR], 1.10; 95% CI: 1.06-1.14) and AF (HR, 1.05; 95% CI: 1.01-1.10) after full adjustment, but not with HF (HR, 1.05; 95% CI: 0.98-1.11) or stroke (HR, 0.94; 95% CI: 0.87-1.02). Associations were strongest in overweight individuals without diabetes. No significant interaction was observed between OSA risk and genetic CVD susceptibility.

Conclusion: High OSA risk independently increases CHD and AF risk in MAFLD, particularly among overweight individuals without diabetes, suggesting targeted intervention may be beneficial.

Keywords

cardiovascular disease / genetic susceptibility / metabolic dysfunction-associated fatty liver disease / obstructive sleep apnea

References

[1] Eslam M, Sanyal AJ, George J, et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999-2014.e1991. https://doi.org/10.1053/j.gastro.2019.11.312

[2] Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335-1347. https://doi.org/10.1097/hep.0000000000000004

[3] Arslan U, Yenerçağ M. Relationship between non-alcoholic fatty liver disease and coronary heart disease. World J Clin Cases. 2020;8(20):4688-4699. https://doi.org/10.12998/wjcc.v8.i20.4688

[4] Mantovani A, Petracca G, Csermely A, et al. Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analyses of about 11 million individuals. Gut. 2022;72(2):372-380.

[5] Gong H, Liu X, Cheng F. Relationship between non-alcoholic fatty liver disease and cardiac arrhythmia: a systematic review and meta-analyses. J Int Med Res. 2021;49(9):3000605211047074. https://doi.org/10.1177/03000605211047074

[6] Byrne CD, Targher G. Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications. Diabetes Obes Metab. 2022;24(suppl 2):28-43. https://doi.org/10.1111/dom.14484

[7] Ismaiel A, Dumitraşcu DL. Cardiovascular risk in fatty liver disease: the liver-heart axis-literature review. Front Med. 2019;6:202. https://doi.org/10.3389/fmed.2019.00202

[8] Anderson N, Tran P. Obstructive sleep apnea. Prim Care. 2025;52(1):47-59. https://doi.org/10.1016/j.pop.2024.09.007

[9] Senaratna CV, Perret JL, Lodge CJ, et al. Prevalence of obstructive sleep apnea in the general population: a systematic review. Sleep Med Rev. 2017;34:70-81. https://doi.org/10.1016/j.smrv.2016.07.002

[10] Yeghiazarians Y, Jneid H, Tietjens JR, et al. Obstructive sleep apnea and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021;144(3):e56-e67. https://doi.org/10.1161/cir.0000000000000988

[11] Li L, Shi Q, Fang B, et al. Functional connectivity changes in primary motor cortex subregions of patients with obstructive sleep apnea. Brain Behav. 2025;15(7):e70698. https://doi.org/10.1002/brb3.70698

[12] Li L, Liu Y, Shu Y, et al. Altered functional connectivity of cerebellar subregions in male patients with obstructive sleep apnea: a resting-state fMRI study. Neuroradiology. 2024;66(6):999-1012. https://doi.org/10.1007/s00234-024-03356-5

[13] Aron-Wisnewsky J, Clement K, Pépin JL. Nonalcoholic fatty liver disease and obstructive sleep apnea. Metabolism. 2016;65(8):1124-1135. https://doi.org/10.1016/j.metabol.2016.05.004

[14] Sudlow C, Gallacher J, Allen N, et al. UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12(3):e1001779. https://doi.org/10.1371/journal.pmed.1001779

[15] Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202-209. https://doi.org/10.1016/j.jhep.2020.03.039

[16] Bedogni G, Bellentani S, Miglioli L, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6(1):33. https://doi.org/10.1186/1471-230x-6-33

[17] Wu H, Wei J, Chen W, et al. Leisure sedentary behavior, physical activities, and cardiovascular disease among individuals with metabolic dysfunction-associated fatty liver disease. Arterioscler Thromb Vasc Biol. 2024;44(9):e227-e237. https://doi.org/10.1161/atvbaha.124.321214

[18] Xiao T, Christian B. Sleep characteristics and HbA1c in patients with type 2 diabetes on glucose-lowering medication. BMJ Open Diabetes Res Care. 2020;8(1):e001702.

[19] Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018;562(7726):203-209. https://doi.org/10.1038/s41586-018-0579-z

[20] Auton A, Brooks LD, Durbin RM, et al. A global reference for human genetic variation. Nature. 2015;526(7571):68-74. https://doi.org/10.1038/nature15393

[21] van der Harst P, Verweij N. Identification of 64 novel genetic loci provides an expanded view on the genetic architecture of coronary artery disease. Circ Res. 2018;122(3):433-443. https://doi.org/10.1161/circresaha.117.312086

[22] Nielsen JB, Thorolfsdottir RB, Fritsche LG, et al. Biobank-driven genomic discovery yields new insight into atrial fibrillation biology. Nat Genet. 2018;50(9):1234-1239. https://doi.org/10.1038/s41588-018-0171-3

[23] Shah S, Henry A, Roselli C, et al. Genome-wide association and Mendelian randomisation analyses provide insights into the pathogenesis of heart failure. Nat Commun. 2020;11(1):163. https://doi.org/10.1038/s41467-019-13690-5

[24] Malik R, Chauhan G, Traylor M, et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. Nat Genet. 2018;50(4):524-537. https://doi.org/10.1038/s41588-018-0058-3

[25] Foster HME, Celis-Morales CA, Nicholl BI, et al. The effect of socioeconomic deprivation on the association between an extended measurement of unhealthy lifestyle factors and health outcomes: a prospective analyses of the UK Biobank cohort. Lancet Public Health. 2018;3(12):e576-e585. https://doi.org/10.1016/s2468-2667(18)30200-7

[26] Wang M, Zhou T, Li X, et al. Baseline vitamin D status, sleep patterns, and the risk of incident type 2 diabetes in data from the UK Biobank study. Diabetes Care. 2020;43(11):2776-2784. https://doi.org/10.2337/dc20-1109

[27] Tietjens JR, Claman D, Kezirian EJ, et al. Obstructive sleep apnea in cardiovascular disease: a review of the literature and proposed multidisciplinary clinical management strategy. J Am Heart Assoc. 2019;8(1):e010440. https://doi.org/10.1161/jaha.118.010440

[28] Valensi P, Benmohammed K, Zerguine M. Bidirectional interplay of sleep apnea syndrome and cardio-vascular disorders in diabetes. Diabetes Res Clin Pract. 2025;220:111984. https://doi.org/10.1016/j.diabres.2024.111984

[29] Pejovic S, Vgontzas AN, Fernandez-Mendoza J, et al. Effect of age on the association of obstructive sleep apnea with metabolic syndrome among obese and non-obese adults. J Clin Sleep Med. 2025;16:1434889. https://doi.org/10.3389/fpsyt.2025.1434889

[30] Gottlieb DJ, Yenokyan G, Newman AB, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the Sleep Heart Health Study. Circulation. 2010;122(4):352-360. https://doi.org/10.1161/circulationaha.109.901801

[31] Shah NA, Yaggi HK, Concato J, Mohsenin V. Obstructive sleep apnea as a risk factor for coronary events or cardiovascular death. Sleep Breath. 2010;14(2):131-136. https://doi.org/10.1007/s11325-009-0298-7

[32] Adderley NJ, Subramanian A, Toulis K, et al. Obstructive sleep apnea, a risk factor for cardiovascular and microvascular disease in patients with type 2 diabetes: findings from a population-based cohort study. Diabetes Care. 2020;43(8):1868-1877. https://doi.org/10.2337/dc19-2116

[33] Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med. 2005;353(19):2034-2041. https://doi.org/10.1056/nejmoa043104

[34] Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1 suppl):S47-S64. https://doi.org/10.1016/j.jhep.2014.12.012

[35] O'Donnell MJ, Chin SL, Rangarajan S, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet. 2016;388(10046):761-775. https://doi.org/10.1016/S0140-6736(16)30506-2

[36] Ji Y, Liang Y, Mak JCW, Ip MS. Obstructive sleep apnea, intermittent hypoxia and non-alcoholic fatty liver disease. Sleep Med. 2022;95:16-28. https://doi.org/10.1016/j.sleep.2022.04.006

[37] Badran M, Ayas N, Laher I. Insights into obstructive sleep apnea research. Sleep Med. 2014;15(5):485-495. https://doi.org/10.1016/j.sleep.2014.01.009

[38] Zucker IH, Xiao L, Haack KK. The central renin-angiotensin system and sympathetic nerve activity in chronic heart failure. Clin Sci (Lond). 2014;126(10):695-706. https://doi.org/10.1042/cs20130294

[39] Giampá SQC, Lorenzi-Filho G, Drager LF. Obstructive sleep apnea and metabolic syndrome. Obesity. 2023;31(4):900-911.

[40] Zhang L, Hou Y, Po SS. Obstructive sleep apnoea and atrial fibrillation. Arrhythm Electrophysiol Rev. 2015;4(1):14-18. https://doi.org/10.15420/aer.2015.4.1.14

[41] Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020;69(9):1691-1705. https://doi.org/10.1136/gutjnl-2020-320622

[42] Ding Y, Deng Q, Yang M, Niu H, Wang Z, Xia S. Clinical classification of obesity and implications for metabolic dysfunction-associated fatty liver disease and treatment. Diabetes Metab Syndr Obes. 2023;16:3303-3329. https://doi.org/10.2147/dmso.s431251

[43] Drożdż K, Nabrdalik K, Hajzler W, Kwiendacz H, Gumprecht J, Lip GYH. Metabolic-associated fatty liver disease (MAFLD), diabetes, and cardiovascular disease: associations with fructose metabolism and gut microbiota. Nutrients. 2021;14(1):103. https://doi.org/10.3390/nu14010103

RIGHTS & PERMISSIONS

2026 The Author(s). Sleep Research published by John Wiley & Sons Australia, Ltd on behalf of Chinese Sleep Research Society.